Eisai Company, Ltd. Receives Approval to Market Anticancer Agent Halaven® in Australia

Published: Sep 10, 2012

Tokyo, Sept 7, 2012 - (JCN Newswire) - Eisai Co., pharmaceutical sales subsidiary Eisai Australia Pty. Ltd. has received approval from the Australian Department of Health and Aging to market the anticancer agent Halaven(R) (eribulin mesylate) for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments.

Back to news